1. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
- Author
-
Isidro Jarque, Erik de Cabo, Marta Gómez-Nuñez, Elsa López-Ansoar, Gloria Pérez-Rus, María Yera Cobo, Fernando Fernández-Fuertes, Germán Perdomo, Pável E Olivera, María Jesús Peñarrubia, Estefanía Bolaños, María Paz Martínez Badas, Isabel Caparrós, Blanca Sanchez-Gonzalez, Angeles Fernández-Rodríguez, Luis Javier García-Frade, Tomás José González-López, Carmen Fernández-Miñano, Jose Angel Hernandez-Rivas, Silvia Bernat, Inmaculada Soto, Violeta Martínez-Robles, and Cristina Pascual
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Secondary ,Population ,Eltrombopag ,Lymphoproliferative disorders ,Comorbidity ,Benzoates ,chemistry.chemical_compound ,Elderly ,Interquartile range ,immune system diseases ,Immune thrombocytopenia, elderly, eltrombopag, primary, secondary ,hemic and lymphatic diseases ,Sistema cardiovascular-Enfermedades ,Humans ,Medicine ,education ,Adverse effect ,Cardiovascular system-Diseases ,Aged ,Retrospective Studies ,Aged, 80 and over ,Purpura, Thrombocytopenic, Idiopathic ,education.field_of_study ,business.industry ,Age Factors ,Hematology ,General Medicine ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Immune thrombocytopenia ,Clinical trial ,Hydrazines ,Treatment Outcome ,chemistry ,Cohort ,Pyrazoles ,Drug Therapy, Combination ,Female ,Headaches ,medicine.symptom ,business ,Biomarkers ,Primary - Abstract
[Background]: Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old population., [Methods]: A total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated., [Results]: Median age of our cohort was 76 (interquartile range, IQR, 70‐81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8‐21) days. Median time on response was 320 (IQR, 147‐526) days. Sixty‐three adverse events (AEs), mainly grade 1‐2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self‐limited pulmonary embolisms in secondary ITP were the only thrombotic events observed., [Conclusion]: Eltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD‐ITP were poor. A relatively high number of deaths were observed.
- Published
- 2020